The
following financial instruments were not included in the diluted loss per share calculations as of the six months ended June 30, 2026,
and 2025 because their effect was anti-dilutive:
Schedule of Anti-dilutive Loss Per Share
| | |
June 30, 2026 | | |
June 30, 2025 | |
| Warrants to purchase common stock | |
| 827,496 | | |
| 205,293 | |
| | |
| | | |
| | |
| Options | |
| 1,860,526 | | |
| 1,436,153 | |
| | |
| | | |
| | |
| Restricted stock awards units | |
| 450,284 | | |
| 424,656 | |
| | |
| | | |
| | |
| Total | |
| 3,138,306 | | |
| 2,066,102 | |
|